View this email in your browser


We have chosen to dedicate this newsletter to NeoNavia's exciting clinical program, which will enable us to strengthen our profile, as it is in a clinical setting. Customers are always keen to see a company's investment in clinical programs, as it demonstrates the belief and commitment in the product long-term. 

We also have plans to start a Registry on the use of NeoNavia, in Germany, which will allow us to gather real world data for our product. Such real world data and evidence appeal to both physicians and authorities, as it can help support NeoNavia, when looking at patient outcomes and health economics. 

This month:

  • Read about the UK COMPULSE study 
  • Watch our June Q&A session with Redeye 

Axilla biopsies are known to be quite technically challenging and often are performed by experienced radiologists, due to their anatomical location, e.g. near a major vessel or nerves. It was these challenges that drove the innovation of the unique open-tip needle, from the Karolinska institute, in Sweden.

Preclinical study results are now being further validated and studied in clinical practice, as part of the UK based, COMPULSE study.

COMPULSE Overview:
  • Compares FlexiPulse (open-tip needle) Vs Current standard core needle in, USG axilla biopsies
  •  Principal investigator is Dr Sarah Vinnicombe, Lead Breast Radiologist at Thirlestaine Breast Centre, Cheltenham 
  • Recruitment is well underway at 12 key hospitals in the UK
"I am delighted to be CI for the COMPULSE study. NeoNavia shows great potential as a biopsy system and the FlexiPulse needle option being used in COMPULSE could prove very useful when it comes to taking biopsies of difficult to access lesions such as lymph nodes in the axilla." Dr Sarah Vinnicombe, Lead Breast Radiologist, Thirlestaine Breast Centre, Gloucs NHS Foundation Trust

NeoDynamics continue to gather extremely valuable clinical experience and data with NeoNavia's FlexiPulse, which includes the recent PULSE data which was presented by Professor Marc Thill, at the SBI/ACR Breast Imaging Symposium, in Savannah. 

REDEYE Q&A with Anna Eriksrud (CEO) and Aaron Wong (CFO)
Watch our recent June Q&A presentation (14 mins)
Over the summer period we will engage with customers at key congresses and events, which will continue to give more customers, hands-on-experience of NeoNavia. 

We wish you a lovely summer and look forward to updating you on these events in September. 

Kind Regards,

Anna Eriksrud
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.
About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

Tweet Tweet
Forward Forward
Share Share
Copyright © 2022 NeoDynamics, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp